NIAID initiates Phase III HPTN 083 trial of anti-HIV drug

The National Institute of Allergy and Infectious Diseases (NIAID) in the US has initiated the Phase III HPTN 083 trial of cabotegravir and truvada to treat men and transgender women with HIV.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news